The global anti-inflammatory therapeutics market size was valued at USD 115.79 billion in 2025 and is projected to grow from USD 119.95 billion in 2026 to USD 159.05 billion by 2034, registering a CAGR of 3.59% during the forecast period from 2026 to 2034. North America dominated the anti-inflammatory therapeutics market with a market share of 38.4% in 2025.
Anti-inflammatory therapeutics are medications designed to reduce inflammation, a natural response by the body to injury, infection, or conditions such as arthritis and inflammatory bowel disease (IBD). The major factors contributing to the growth of the global anti-inflammatory therapeutics market are the increasing prevalence of inflammatory diseases, ongoing technological advancements in drug delivery systems, and a growing number of regulatory approvals for anti-inflammatory therapeutics.
These drugs target pathways involved in inflammation to alleviate pain, swelling, and tissue damage. Common categories of anti-inflammatory drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. By reducing inflammation, these therapeutics help manage chronic conditions, improve quality of life, and prevent further complications from prolonged inflammation.
Download a Free Sample To learn more about this report,
Stem cell therapies are being investigated for their ability to repair damaged tissues and regulate the immune system in chronic inflammatory conditions. By promoting tissue regeneration, stem cells can help restore function in joints and other affected areas. In rheumatoid arthritis (RA) and osteoarthritis, stem cells may reduce inflammation and slow disease progression. These therapies offer the potential for long-term relief by targeting the root causes of inflammation and joint damage.
For instance, in January 2024, according to news by the University of York, a spin-out company from the University of York is working on developing a novel treatment derived from engineered human stem cells to combat arthritic diseases in both adults and children.
Therefore, stem cells can modulate immune responses, potentially reducing the need for continuous drug treatments.
The integration of digital health tools with anti-inflammatory therapeutics is revolutionizing disease management, offering real-time monitoring of disease progression. Wearable devices now track vital signs, inflammation markers, and physical activity, providing valuable insights into patients' conditions.
Mobile apps allow patients to log symptoms, medication use, and lifestyle factors, enhancing treatment adherence. Moreover, telemedicine solutions enable healthcare providers to adjust therapies remotely, reducing the need for in-person visits.
By combining these technologies with traditional therapies, personalized care can be better achieved, enhancing the overall management of chronic inflammatory diseases.
The increasing prevalence of inflammatory diseases such as arthritis, inflammatory bowel disease (IBD), and psoriasis is becoming a major global health concern. Alongside this, genetic factors and heightened immune responses have contributed to the rise in autoimmune-related inflammatory disorders. Advances in diagnostic tools and greater awareness are also revealing more cases, particularly among younger populations.
The growing burden of these diseases amplifies the need for effective therapeutic solutions to address inflammation and improve patients' quality of life.
The surge in research and development (R&D) within the global market has been a driving force behind its growth. Pharmaceutical companies are investing significantly in discovering new compounds and innovative drug delivery systems to enhance the effectiveness and safety of anti-inflammatory treatments.
These R&D efforts are pushing the development of biologics and targeted therapies designed to precisely modulate immune responses, thereby improving patient outcomes in conditions like rheumatoid arthritis and IBD.
Safety concerns and side effects associated with long-term use of anti-inflammatory drugs such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) present significant challenges. These medications can cause gastrointestinal issues like ulcers, bleeding, and an increased risk of cardiovascular events, including heart attacks and strokes.
Moreover, chronic corticosteroid use may lead to weight gain, bone loss, and hormonal imbalances. Biological therapies, while effective, can suppress the immune system, increasing the risk of infections and other complications. These safety concerns require careful monitoring, which limits the widespread use of certain anti-inflammatory medications.
The advancement of targeted biologic therapies is reshaping the treatment of immune-mediated inflammatory diseases, providing more precise and effective treatment options. These biologics are designed to specifically target immune system components, such as cytokines or immune cells, which play crucial roles in the inflammatory process.
By targeting specific immune pathways, biologics can offer higher precision and reduce the risk of systemic side effects, a significant advantage over traditional therapies. These benefits are driving the growth of the global market as biologics become a cornerstone of modern treatment regimens for chronic inflammatory diseases.
The global anti-inflammatory therapeutics market is segmented into drug class, indication, and distribution channel.
Anti-inflammatory biologics segment dominates the market with the largest market revenue
The anti-inflammatory biologics segment leads the market, driven by their effectiveness in treating chronic inflammatory conditions. Drugs like TNF inhibitors and interleukin inhibitors target specific immune molecules to reduce inflammation, providing relief for patients with conditions unresponsive to NSAIDs or corticosteroids. The rising prevalence of autoimmune disorders and the approval of new biological therapies further boost demand.
Request Customizationto receive a tailored report.
Arthritis segment dominates the market with the largest market revenue
Arthritis holds the largest share of the global market due to the growing prevalence of the condition and the effectiveness of anti-inflammatory treatments. Therapies, particularly biologics, have been instrumental in managing symptoms and improving the quality of life for patients.
Hospital pharmacies segment dominates the market with the largest market revenue
Hospital pharmacies dominate the global market primarily due to their role in managing biologic treatments and advanced therapies. Hospitals provide the specialized infrastructure needed for storing and administering biologics, ensuring proper handling and patient care. As treatment centers for severe conditions like rheumatoid arthritis and ulcerative colitis, hospital pharmacies offer expertise in prescribing these advanced medications. Their pivotal role in the treatment of chronic inflammatory conditions solidifies their leadership in the market.
Speak to an Analystto discuss market opportunities.
U.S. – The U.S. market thrives on its advanced healthcare infrastructure, substantial health expenditure, and leading pharmaceutical research. The widespread prevalence of inflammatory conditions such as arthritis and IBD further fuels growth. For example, in June 2024, Amgen presented 27 abstracts at the European Alliance of Associations for Rheumatology's (EULAR) Congress, showcasing its commitment to developing novel therapies for inflammatory and rheumatic diseases.
Canada – Canada’s market is expanding due to improved healthcare access, a large patient population, and increasing cases of autoimmune and inflammatory diseases. In October 2024, Crohn’s & Colitis Canada reported that over 322,000 Canadians are affected by Crohn’s disease or ulcerative colitis, with numbers expected to rise to 470,000 by 2035. This growing patient pool contributes significantly to demand for targeted treatments.
Unlock Regional Insightsto access country-level data, & regional trends.
Germany – Germany's market is driven by its emphasis on healthcare innovation and high demand for advanced therapies. The country's focus on developing new treatments for chronic inflammatory conditions, coupled with strong investment in research, fuels market expansion. Germany also benefits from a well-established healthcare system that supports the adoption of innovative anti-inflammatory biologics.
UK – In the UK, rising awareness and acceptance of innovative therapies among healthcare professionals and patients are propelling demand for anti-inflammatory therapeutics. Additionally, growing demand for biologics and advancements in immunology research support growth. For instance, in February 2024, Queen Mary University of London researchers reported findings related to RvT4 and natural defenses against atherosclerosis in rheumatoid arthritis patients.
France – France's anti-inflammatory therapeutics market is influenced by the increasing number of patients with chronic inflammatory diseases. A growing focus on improving treatment of these conditions contributes to expansion. For example, in October 2024, Université de Lille reported that chronic inflammatory diseases affect 4 million people in France, highlighting the substantial healthcare burden associated with these conditions.
China – China's market is expanding due to rapid urbanization, rising healthcare expenditure, and innovative research. The country's large population and growing health awareness further support growth. In July 2024, Everest Medicines treated its first Chinese patient with zetomipzomib, a novel immunoproteasome inhibitor for lupus nephritis, in the Phase 2b PALISADE trial.
Japan – Japan’s aging population and increasing prevalence of inflammatory diseases, including inflammatory bowel disease, arthritis, and respiratory conditions, are driving demand. The need for advanced therapies to manage these conditions continues to increase as Japan addresses the healthcare requirements of its aging demographic. Treatment innovation, particularly in biologics and immunotherapy, is further supporting development.
India – In India, demand is growing due to the rising prevalence of autoimmune and chronic diseases, an aging population, and lifestyle changes. Improved healthcare access, greater awareness, and expanding availability of biosimilars are contributing to growth. India’s strong pharmaceutical manufacturing sector and government support also help improve access to advanced treatments. In January 2023, Sun Pharma's acquisition of three drug brands expanded its anti-inflammatory portfolio.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Middle East And Africa Neurodegenerative Diseases Market Growth Trends 2034
North America Neurodegenerative Disease Market Size, 2034
Europe Neurodegenerative Disease Market Size, Share & Trends 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
NASH Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com